This treatment regime was sufficient to generate a 1.9-fold increase in SMN levels in the brain of SMA embryos compared with SMA embryos that did not undergo any therapeutic intervention (Figure 6, A and B, and Supplemental Figure 7A). The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.